Bastiano Sanna, EVP, Cell & Genetic Therapies at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 7,450 shares at $275.23 ($2.0M) on 2022-04-05, disclosed to the SEC on 2022-04-06.
Open-market sale of $2.0M VRTX by EVP, Cell & Genetic Therapies. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $267.10 | 305 | $81K | 4.0% |
| 2 | $267.10 | 305 | $81K | 4.0% |
| 3 | $268.43 | 257 | $69K | 3.4% |
| 4 | $268.43 | 257 | $69K | 3.4% |
| 5 | $275.23 | 3,163 | $871K | 42.6% |
| 6 | $275.23 | 3,163 |
| $871K |
| 42.6% |
| Total | $274.10 avg | 7,450 | $2.0M | 100% |
| Filing → |
| VRTX | SELL | 2023-04-14 | $4.9M | — | Filing → |
| VRTX | SELL | 2023-04-06 | $231K | — | Filing → |
| VRTX | SELL | 2023-03-20 | $1.7M | — | Filing → |